Back to results
US 2025/0084038 A1Published application
Pparg inverse agonists and uses thereof
AssigneeFlare Therapeutics Inc.
InventorsJonathan E. Wilson, James E. Audia, Jacob I. Stuckey
Life of this patent
Estimating the term…
Abstract
Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with PPARG.
Claims32
A compound having the Formula I:
- or a pharmaceutically acceptable salt thereof, wherein
- R1 is hydrogen, halo, (C1-C4)alkyl, or hydroxyl;
- X is S, SO, SO2, or —SONH;
- R2 is (C1-C4)alkyl, (C1-C4)alkoxy, or halo(C1-C4)alkyl;
- R3 is cyano or nitro;
- R4 is hydrogen, halo, (C1-C4)alkyl, (C1-C4)alkoxy, or hydroxyl;
- R5 is halo, halo (C1-C4)alkyl, or cyano;
- R6 is halo, halo (C1-C4)alkyl, (C1-C4)alkyl, or cyano;
- R7 is halo, (C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkyl, halo (C1-C4)alkoxy, —(C1-C4)alkylORa, —(C1-C4)alkylC(O)Ra, —(C1-C4)alkylC(O)ORa, —C(O)NRaRb, —(C1-C4)alkylC(O)NRaRb, —C(O)Ra, —C(O)ORa, —NRaRb, —(C1-C4)alkyINRaRb, —C(O)NRaSO3H, —NRaC(O)Rb, —NRaC(O)ORb, —NRaC(S)ORb, —NRCC(O)NaRb, —NRC(S)NRaRb, —NRCS(O)2NRaRb, —C(S)Ra, —S(O)2Ra, —S(O)Ra, —C(S)ORb, —C(S)NRaRb, —NRaC(S)Rb, —SRa, phenyl, 4- to 6-membered heterocyclyl, and 5- to 7-membered heteroaryl, wherein each of said phenyl, 4- to 6-membered heterocyclyl, and 5- to 7-membered heteroaryl are optionally and independently substituted with 1 to 3 groups selected from R8;
- R8 is selected from halo, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4) alkoxy, nitro, oxo, cyano, —(C1-C4)alkylORd, —(C1-C4)alkyIC(O)Rd, —(C1-C4)alkylC(O)ORd, —C(O)NRdRe, —(C1-C4)alkylC(O)NRdRe, —C(O)Rd, —C(O)ORd, —NRdRe, —(C1-C4)alkyINRdRe, —C(O)NRdSO3H, —NRdC(O)Re, —NRdC(O)ORe, —NRfC(S)ORe, —NRfC(O)NdRe, —NRfC(S)NRdRe, —NRfS(O)2NRdRe, —C(S)Rd, —S(O)2Rd, —S(O)Rd, —C(S)ORd, —C(S)NRdRe, —NRdC(S)Re, and —SRd;
- Ra, Rb, Rc, Rd, Re, and Rf are each independently hydrogen or (C1-C4)alkyl;
- and
- q and r are each independently 0 or 1.
10 more elements
(canceled)
(canceled)
11-13. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
31-37. (canceled)
40-66. (canceled)
Dependencies are inferred from the claim text.